South Africa’s HIV Patients At Risk As U.S. Aid Freeze Disrupts Treatment

In a rural village in South Africa’s KwaZulu-Natal province, 19-year-old Nozuko Majola struggles to secure transport for her life-saving HIV medication.

The mobile clinic that once delivered it to her doorstep can no longer reach her due to the ongoing freeze of U.S. foreign aid, raising fears of increased treatment defaults and a surge in infection rates.

The crisis stems from former U.S. President Donald Trump’s suspension of the President’s Emergency Plan for AIDS Relief (PEPFAR), which contributes over $400 million annually to South Africa’s HIV programs.

The move threatens the care of 5.5 million South Africans on antiretroviral treatment, with KwaZulu-Natal—home to 1.9 million HIV-positive individuals—hit particularly hard.

While a U.S. federal judge recently ordered a temporary lifting of the freeze, many aid organizations have already shut down, leaving patients scrambling for alternatives.

The closures have forced an influx of HIV patients into overstretched public healthcare facilities, while thousands of PEPFAR-funded health workers now face unemployment.

Health advocates warn that without immediate intervention, South Africa’s efforts to curb HIV could unravel.

“We once aimed for an HIV-free generation by 2030,” said long-time patient Nozuko Ngcaweni. “But if this continues, we will be dealing with more deaths.”

Mzamo Zondi, a provincial manager of the Treatment Action Campaign, called the situation dire.

“Our response to HIV is likely to falter as we struggle to prevent new infections. This is a matter of life and death.”